L20.9 L20.8
Conditions
Interventions
Group 1: Only one study arm
There are no study interventions as such.
Up to 50 ml of blood will be collected at the routine visits at week 0, week 2, week 12 and week 52 after initiation of a new sy
Sponsors
Department of Dermatology and AllergyUniversity Hospital Schleswig-Holstein (UKSH)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Written informed consent from the study participant prior to performing any study-related activities. 2) Age = 18 years at the time of study entry. 3) Clinically diagnosed atopic dermatitis. 4) Initiation of systemic therapy for atopic dermatitis by the treating physician as part of routine care 5) Study participant agrees and, in the judgment of study personnel, is able to comply with the study protocol for the duration of the study
Exclusion criteria
Exclusion criteria: 1) Study participant is not capable of consenting to study participation or adhering to the study protocol. 2) Tendency to keloid/hypertrophic scarring and/or known wound healing disorder. 3) Tattooing and/or skin lesions due to a dermatosis in the puncture area not investigated in this study 4) Needle phobia 5) Pregnancy 6) Liver/biliary tract disease present at the time of the study and judged unstable by the study physician, manifested by ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent jaundice, and/or liver cir-rhosis 7) Known allergy and/or hypersensitivity to the materials used. 8) Any reason that, in the opinion of the study physician, may prevent safe participation of the study participant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differentially expressed genes at week 2 as compared to baseline Differentially expressed genes at week 12 as compared to baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical response at week 12 after treatment start, defined as relative and absolute change in Eczema Area and Severityx Index (EASI) Multiple physician- und patient-reported outcomes | — |
Countries
Germany
Contacts
Public ContactStephan Weidinger
Department of Dermatology and AllergyUniversity Hospital Schleswig-Holstein (UKSH)
Outcome results
None listed